Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-cypermethrin is a highly active synthetic Type II pyrethroid insecticide consisting of the two most biologically active stereoisomers of cypermethrin (the (1R,cis)-alpha-S and (1S,cis)-alpha-R enantiomers). It acts as a potent modulator of voltage-gated sodium channels in insect neurons, delaying channel inactivation and causing prolonged sodium influx, which leads to repetitive nerve firing, hyperexcitation, paralysis, and death. Originally developed by Shell International Chemical Company in the 1980s and later acquired/marketed by BASF, FMC, and other agrochemical companies, alpha-cypermethrin is widely used in agriculture to control chewing and sucking pests, in public health for vector control (such as indoor residual spraying and insecticide-treated nets for malaria prevention), and in veterinary medicine to control ectoparasites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-cypermethrin.